Ocular Therapeutix Receives FDA Agreement Under Special Protocol Assessment For Its First Pivotal Clinical Trial Of OTX-TKI In Wet AMD
Portfolio Pulse from Benzinga Newsdesk
Ocular Therapeutix has received FDA agreement under Special Protocol Assessment for its first pivotal clinical trial of OTX-TKI in Wet AMD.
November 01, 2023 | 12:03 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Ocular Therapeutix's stock may see positive movement as the company has received FDA agreement for its first pivotal clinical trial of OTX-TKI in Wet AMD.
The FDA agreement for the clinical trial of OTX-TKI in Wet AMD is a significant milestone for Ocular Therapeutix. This could potentially lead to a new product offering, which could boost the company's revenues in the future. As such, this news is likely to be viewed positively by investors, potentially leading to an increase in the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100